

Enantioselective (3+2) Cycloaddition via N-Heterocyclic Carbene-Catalyzed Addition of Homoenolate to Cyclic N-Sulfonyl Trifluoromethylated Ketimines: Synthesis of Fused N-Heterocycles γ -Lactams

Zhen-Zhen Zhang, Yongna Zhang,* Hui-Xin Duan, Zhuo-Fei Deng and You-Qing Wang*

Henan Provincial Key Laboratory of Polyoxometalate Chemistry, Provincial Key Laboratory of Natural Medicine and Immuno-Engineering, College of Chemistry and Chemical Engineering, Henan University, Kaifeng, Henan 475004, P. R. China.
E-mail: zhangyongna@henu.edu.cn; wyouqing@hotmail.com

Supporting Information

Table of Contents.


1. General Information.....	S1
2. More results on the condition optimization of (3+2) cycloaddition reaction.....	S1-2
3. Preparation of substrates 1 and NHC catalyst C-6.....	S2-5
4. General procedure for NHC-catalyzed (3+2) cycloaddition reaction.....	S5-11
5. Transformations of product 3a.....	S11-13
6. X-ray structure for compound 3e.....	S13
7. Copy of NMR, HRMS and HPLC for new compounds	S14

1. General information

General: ^1H and ^{13}C NMR spectra were recorded on Bruker DRX-300 spectrometers, and ^{19}F NMR spectra were recorded on Bruker DRX-400 spectrometers. The chemical shifts for ^1H NMR were recorded in ppm (δ) relative to tetramethylsilane (TMS) with the solvent resonance employed as the internal standard (CDCl_3 , d 7.26 ppm). The chemical shifts for ^{13}C NMR were recorded in ppm downfield using the central peak of deuteriochloroform (77.0 ppm) as the internal standard. The *ee* values determination was carried out using chiral HPLC with Daicel chiral column on Agilent 1200. Flash column chromatography was performed on silica gel (200-300 mesh). TLC analysis was performed using glass-backed plates coated with 0.2 mm silica. The solvents were distilled from appropriate drying agents prior to use, unless otherwise noted. Cyclic imines were prepared according to the procedures reported in the literature.^[1]

2. More results on the condition optimization of (3+2) annulation reaction

Table S1 Effect of temperature and concentrations^a




^[1] (a) D. V. Sevenard, M. Vorobyev, V. Y. Sosnovskikh, H. Wessel, O. Kazakova, V. Vogel, N. E. Shevchenko, V. G. Nenajdenko, E. Lork and G.- E. Röschenthaler, *Tetrahedron*, 2009, **65**, 7538; (b) B. H. Brodsky and J. D. Bois, *J. Am. Chem. Soc.*, 2005, **127**, 15391; (c) M.-W. Chen, X. C. Mao, Y. Ji, J. j. Yuan, Z. H. Deng and Y. Y. Peng, *Tetrahedron Lett.*, 2019, **60**, 151280.

Entry	Concentration of 1a [mol/l]	T [°C]	Yield [%] ^b	dr ^c	ee [%] ^d
1	0.1	40	90	20:1	98
2	0.1	25	89	20:1	99
3	0.33	25	90	14:1	98
4	0.17	25	89	20:1	94
5	0.13	25	99	14:1	92
6	0.067	25	94	>20:1	99
7	0.05	25	96	>20:1	99

^a Reaction conditions: **1a** (0.05 mmol), **2a** (0.15 mmol). ^b Isolated yield. ^c Determined by ¹H NMR.

^d Determined by HPLC using a chiral column.




Scheme S1 Screening for catalysts

3. Preparation of substrates **1** and NHC catalyst **C-6**

The known cyclic imines **1a**^[1a], **1d**^[1b], **1e**^[1c], **1g**^[1b], **1h**^[1a], **1j**^[1b] were prepared according to the modified procedures in the literature.

3.1 Preparation of substrates **1**


1) Preparation of 2,2,2-trifluoro-2'-hydroxyacetophenone



Typical procedure according to the modified procedure in the literature^[1b]: (**1e** as an example)

S-1e: To a solution of 2-bromo-5-chlorophenol (5.0 g, 25 mmol) and dihydropyran (3.8 mL, 42.5 mmol) in CH₂Cl₂ (15 ml) was added PPTS (628.2 mg, 2.5 mmol). The resulting mixture was stirred at room temperature for 18 h. The reaction was quenched with H₂O, and the product was extracted with CH₂Cl₂. The combined organic layer was washed with brine, dried over Na₂SO₄ and evaporated. The crude mixture was purified by silica gel column chromatography to afford **S-1** (4.94g, 71% yield) as a colorless oil.


S-2e: 1) *n*-Butyllithium (2.5 M in hexanes, 8.2 mL, 21 mmol, 1.2 equiv) was added dropwise to a -78 °C solution of **S-1e** (5.0 g, 17 mmol) in 45 mL of THF. The resulting **S-1e** suspension was stirred at -78 °C for 20 min, then neat ethyl trifluoroacetate (4.0 mL, 34 mmol, 2.0 equiv) was added via syringe. The precipitate dissipated, and the homogenous solution was stirred for 1.5 h at -78 °C. The reaction was quenched at -78 °C by the addition of 20 mL of a 1/2 saturated aqueous NH₄Cl. The mixture was transferred to a separatory funnel, the organic layer was collected, and the aqueous layer was extracted with 3 x 15 mL of Et₂O. The combined organic extracts were washed with 15 mL saturated aqueous NaCl, dried over anhydrous MgSO₄, and concentrated under reduced pressure to afford an oily residue. 2) The unpurified material was dissolved in 20 mL of EtOH and to the solution was added PPTS (427.2 mg, 1.7 mmol). The resulting solution was reflux for 12 h. The mixture was concentrated under reduced pressure, and then was extracted with 3 x 30 mL of ether, dried over MgSO₄. Purification by chromatography on silica gel (Pentane) furnished the desired 2,2,2-trifluoro-2'-hydroxyacetophenone as a colorless oil. The determined purity of **S-2e** by nuclear magnetic internal standard method is 52%.



To an ice cold solution of 5-bromosalicylaldehyde **S-3** (1g, 5 mmol) and TMSCF₃ (853 mg, 6 mmol, 1.2 equiv) in 8 mL of THF was added 1 mL TBAF (1.0 M in THF, 20 mol%). The solution was reflux for 10 h. Following this time, a 4.4 M aqueous solution of HCl (10 mL) was slowly added. The mixture was stirred for 1 h then diluted with 10 mL of EtOAc, and solid Na₂CO₃ was cautiously added. Once effervescence had ceased, the solution was dried over MgSO₄, filtered and concentrated under reduced pressure. Purification of this material by chromatography on silica gel afforded the desire product **S-4** (731.7 mg, 54%).

To a solution of **S-4** (1.08 g, 4 mmol) in 15 mL of CH₂Cl₂ was added TEMPO (0.2 mmol, 31.2 mg) followed by PhI(OAc)₂ (2.56 g, 8 mmol). The mixture was stirred for 13 h and quenched by the addition of 1.0 M aqueous Na₂S₂O₃. The mixture was transferred to a separatory funnel and the organic layer was collected. The aqueous layer was extracted with 3 x 20 mL of CH₂Cl₂. The combined organic fractions were dried over Na₂SO₄, and concentrated under reduced pressure. Purification of crude product by chromatography on silica gel afforded the desired product **S-2f** (699.4 mg, 65%).

2) Preparation of cyclic N-sulfonyl trifluoromethylated ketimines 1:



S-2b, S-2c, S-2f, S-2i, S-2k, S-2l

ClSO_2NH_2 was prepared by HCOOH and ClSO_2NCO in situ: To an ice cold solution, anhydrous formic acid (1.38g, 30 mmol) was dropwise slowly to the flask of ClSO_2NCO (4.24g, 30 mmol), then stirred at room temperature until there were no bubbles. The resulting solid was ClSO_2NH_2 , It is directly used in the follow reaction. To a solution of 2-trifluoroacetylphenol **S-2** in DMA was quickly transferred solid $\text{H}_2\text{NSO}_2\text{Cl}$ (3.0 equiv.). **Caution:** a mild exotherm was noted upon combining these reagents. After stirring for 12 h, the reaction was quenched by the addition of 3 mL of H_2O and transferred to a separatory funnel with 10 mL of Et_2O . The organic layer was separated, and the aqueous layer was extracted with 3 x 5 mL of Et_2O . The combined organic layers were washed successively with 2 x 3 mL of H_2O and 1 x 5 mL of brine, dried over MgSO_4 , and concentrated under reduced pressure. Purification by chromatography on silica gel afforded the desired cyclic ketimines **1**.

1b: 1.83 g, yield: 61%, colorless oil; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.64-7.58 (m, 2H), 7.45 (q, $J = 4.3$ Hz 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 159.2 (d, $J = 249.1$ Hz), 151.1 (d, $J = 2.5$ Hz), 126.3 (d, $J = 24.1$ Hz), 121.5 (d, $J = 8.1$ Hz), 118.1 (q, $J = 279.6$ Hz), 114.8 (q, $J = 3.3$ Hz), 114.5 (q, $J = 3.3$ Hz), 112.1 (d, $J = 8.5$ Hz); $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -67.39, -110.88; HRMS (ESI): m/z calculated for $\text{C}_8\text{H}_4\text{F}_4\text{NO}_3\text{S}^+$ ($\text{M}+\text{H}$)⁺ 269.9843, found: 269.9833.

1c: 0.78 g, yield: 58%, m.p. 62.1-62.3 °C $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 8.03-7.98 (m, 1H), 7.27-7.21 (m, 1H), 7.17-7.14 (m, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 160.5, 157.8, 154.9 (d, $J = 3.9$ Hz), 139.6 (d, $J = 11.5$ Hz), 117.8 (q, $J = 278.6$ Hz), 115.6 (d, $J = 3.7$ Hz), 114.8 (d, $J = 26.4$ Hz), 103.5 (d, $J = 17.3$ Hz); $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -70.31, -70.40, -98.02, -98.12; HRMS (ESI): m/z calculated for $\text{C}_8\text{H}_4\text{F}_4\text{NO}_3\text{S}^+$ ($\text{M}+\text{H}$)⁺ 269.9843, found 269.9852.


1f: 1.83 g, yield: 61%, m.p. 95.7-96.1 °C; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 8.03 (s, 1H), 7.96 (d, $J = 8.9$ Hz, 1H), 7.33 (d, $J = 8.9$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 161.1 (q, $J = 37.8$ Hz), 153.9, 141.5, 130.8 (q, $J = 3.5$ Hz), 121.3, 119.7, 118.1 (q, $J = 279.8$ Hz), 112.8; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -67.04; HRMS (EI): m/z calculated for $\text{C}_8\text{H}_3\text{BrF}_3\text{NO}_3\text{S}^+$ (M)⁺ 328.8964, found: 328.8979.

1i: 1.39 g, yield: 41%, m.p. 60.1-60.3 °C $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.90-7.87 (m, 2H), 7.36-7.33 (m, 1H), 1.37 (s, 9H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 162.4 (q, $J = 37.1$ Hz), 152.9, 150.3, 136.5, 124.7 (q, $J = 3.3$ Hz), 118.4 (q, $J = 279.5$ Hz), 119.1, 111.2, 35.0, 31.0; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -66.84; HRMS (ESI): m/z calculated for $\text{C}_{12}\text{H}_{13}\text{F}_3\text{NO}_3\text{S}^+$ ($\text{M}+\text{H}$)⁺ 308.0563, found: 308.0567.

1k: 1.09 g, yield: 32%, m.p. 109.2-109.4 °C $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 7.41-7.36 (m, 2H), 7.33-7.32 (m, 1H), 3.89 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 162.0 (q, $J = 37.3$ Hz), 157.3, 148.9, 125.6, 120.6, 118.3 (q, $J = 279.6$ Hz), 112.0, 111.2 (q, $J = 3.3$ Hz), 56.1; $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -67.14; HRMS (ESI): m/z calculated for $\text{C}_9\text{H}_7\text{F}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$)⁺ 282.0042, found 282.0045.


11: 1.82 g, yield: 67%, m.p. 137.2-137.6 °C ^1H NMR (300 MHz, CDCl_3): δ 8.30 (d, $J = 8.9$ Hz, 1H), 8.23 (d, $J = 8.4$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 7.82-7.77 (m, 1H), 7.69 (t, $J = 7.5$ Hz, 1H), 7.46 (d, $J = 8.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.0 (d, $J = 37.8$ Hz), 157.3, 141.2, 131.3, 130.3, 129.7, 128.3, 127.8, 125.8 (q, $J = 6.3$ Hz), 118.9 (q, $J = 279.9$ Hz), 117.1, 110.8; ^{19}F NMR (376 MHz, CDCl_3): δ -64.02; HRMS (ESI): m/z calculated for $\text{C}_{12}\text{H}_7\text{F}_3\text{NO}_3\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 302.0093, found 302.0096.

3.2 Preparation of NHC catalyst C-6^[2]



The compound **8** (2.2 mmol) and the hydrazine hydrochloride (2.2 mmol) were dissolved in the mixed solvent of CH_2Cl_2 and MeOH (14 mL, v/v, 1/1) under the protection of argon. HCl (4 M in dioxane, 0.055 mL, 0.22 mmol) was added to the solution. The reaction mixture was stirred at r.t. overnight. The mixture was evaporated to dryness to afford the crude product, which was directly used in the next step without further purification. The crude compound **9** was dissolved in chlorobenzene (6 mL) and then, HC(OEt)_3 (3.3 mL) and HCl (4 M in dioxane, 0.5 mL, 2 mmol) were added. The reaction mixture was heated at 110 °C for 0.5 h. The solvent was removed under reduced pressure and the product was purified via flash column chromatography on silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH} = 15/1$) to afford the triazolium salt as yellow solid 473 mg, 50% yield. $R_f = 0.20$ ($\text{DCM}/\text{MeOH}, 20:1$); ^1H NMR (300 MHz, CDCl_3) δ 12.55 (s, 1H), 8.32 (s, 1H), 8.13 (d, $J = 8.2$ Hz, 1H), 7.40 (d, $J = 8.3$ Hz, 1H), 7.12 (s, 3H), 5.21 (s, 1H), 5.04 (s, 2H), 3.55 (d, $J = 17.4$ Hz, 1H), 3.22 (d, $J = 17.5$ Hz, 1H), 3.15-2.86 (m, 1H), 2.64-2.44 (m, 1H), 2.10-1.90 (m, 1H), 1.37 -0.98 (m, 18H); ^{13}C NMR (75 MHz, CDCl_3) δ 153.5, 148.8, 147.8 (d, $J = 7.7$ Hz), 146.0, 145.6, 145.1, 138.3, 128.4, 126.0, 124.8, 122.7, 122.2, 119.7, 61.8, 60.3, 37.8, 34.5, 29.1, 28.6, 24.4, 24.1, 23.9, 23.7, 23.4; HRMS (ESI) m/z calcd for $\text{C}_{27}\text{H}_{33}\text{N}_4\text{O}_3^+$ ($\text{M}-\text{Cl}$) $^+$ 461.2547, found 461.2544.

4. General procedure for NHC-catalyzed (3+2) cycloaddition reaction



General procedure: The solution of DIPEA (0.02 mmol, 20 mol%) in DCM was added to the mixture of NHC cat. **C-6** (0.02 mmol, 20 mol%) and *N*-sulfonyl ketimines **1** (0.1 mmol). Then the

^[2] (a) S.-X. Dong, M. Frings, H. C. Cheng, J. Wen, D. Zhang, R. Gerhard and B. Carsten , *J. Am. Chem. Soc.*, 2016, **138**, 2166; (b) X.-Y. Chen, Q. Liu, P. Chauhan, S. Li, A. Peuronen, K. Rissanen, E. Jafari and D. Enders, *Angew. Chem. Int. Ed.*, 2017, **56**, 6241.

DCM (2 ml) was added, the α,β -unsaturated aldehydes **2** (0.3 mmol) was added. The reaction bottle was sealed and then stirred at 25 °C in showed reaction time. Direct purification of the crude reaction mixture by column chromatography on a silica gel (PE/EA) gave the desired annulation products. The enantiomeric excess was determined by HPLC, dr was determined by ¹H NMR. Racemic samples for the standard of chiral HPLC spectra were prepared using racemic NHC precursor **C-17** as the catalyst.

(1S,10b*S*)-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2H)-one 5,5-dioxide (3a): R_f = 0.48 (PE/EA, 3:1); White solid, 34.3 mg, 89% yield, 99% ee, >20:1 dr, [α]²⁸_D = 54.7 (c 1.5, CHCl₃); m.p. 149.9-150.4 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.35-7.27 (m, 1H), 7.22-7.12 (m, 4H), 7.05-6.90 (m, 4H), 4.24 (d, J = 8.7 Hz, 1H), 3.41-3.52 (m, 1H), 2.65 (dd, J = 18.0, 2.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 172.4, 149.4, 138.7, 131.6, 129.7 (d, J = 1.8 Hz), 129.4, 128.4, 127.1, 126.3, 124.5 (q, J = 286.7 Hz), 119.4, 118.7, 73.7 (q, J = 30.0 Hz), 45.4, 38.9 (q, J = 2.6 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -76.19, -112.64; HRMS (ESI) m/z calculated for C₁₇H₁₃F₃NO₄S⁺ (M+H)⁺ 384.0512, found 384.0513; HPLC (Chiraldak IC-H column, hexane/iPrOH = 85/15, 1.0 mL/min, 210 nm): t₁ = 14.8 min (major), t₂ = 16.9 min.

(1S,10b*S*)-9-fluoro-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2H)-one 5,5-dioxide (3b): R_f = 0.44 (PE/EA, 3:1); White solid, 32.3 mg, 80% yield, 94% ee, >20:1 dr, [α]²⁸_D = 36.1 (c 1.5, CHCl₃); m.p. 203.0-203.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.25-7.17 (m, 3H), 7.17-7.07 (m, 1H), 7.08-6.95 (m, 3H), 6.69 (dd, J = 8.7, 2.8 Hz, 1H), 4.20 (d, J = 8.7 Hz, 1H), 3.46 (dd, J = 18.2, 8.7 Hz, 1H), 2.69 (d, J = 18.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 171.6, 159.7 (d, J = 247.5 Hz), 145.35 (d, J = 3.0 Hz), 138.2, 129.6, 128.8, 127.0, 124.3 (q, J = 286.7 Hz), 121.1 (d, J = 8.7 Hz), 120.4 (d, J = 8.5 Hz), 118.7 (d, J = 23.6 Hz), 116.7 (d, J = 26.3 Hz), 73.7 (q, J = 32.3 Hz), 45.4, 38.7 (q, J = 2.5 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -76.19, -112.64; HRMS (ESI) m/z calculated for C₁₇H₁₂F₄NO₄S⁺ (M+H)⁺ 402.0417, found 402.0415; HPLC (Chiraldak IC-H column, hexane/iPrOH = 85/15, 1.0 mL/min, 210 nm): t₁ = 12.3 min (major), t₂ = 13.4 min.

(1S,10b*S*)-8-fluoro-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2H)-one 5,5-dioxide (3c): R_f = 0.44 (PE/EA, 3:1); White solid, 37.7 mg, 94% yield, 98% ee, 17:1 dr, [α]²⁸_D = 69.0 (c 1.5, CHCl₃); m.p. 117.6-118.1 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.25-7.14 (m, 3H), 7.09-6.99 (m, 2H), 6.98-6.84 (m, 2H), 6.78-6.67 (m, 1H), 4.21 (d, J = 8.8 Hz, 1H), 3.53-3.38 (m, 1H), 2.67 (dd, J = 18.1, 2.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 171.7, 164.8, 161.4, 150.0 (d, J = 11.9 Hz), 138.44, 131.03 (d, J = 9.7 Hz), 129.6, 128.6, 127.1, 124.4 (q, J = 286.4 Hz), 114.7 (d, J = 4.3 Hz), 114.0 (d, J = 21.9 Hz), 107.7 (d, J = 26.0 Hz), 73.5 (q, J = 30.3 Hz), 45.3, 38.7 (q, J = 2.4 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -70.41, -76.69, -105.04; HRMS (ESI) m/z calculated for C₁₇H₁₂F₄NO₄S⁺ (M+H)⁺ 402.0418, found 402.0414. HPLC (Chiraldak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t₁ = 10.1 min (major), t₂ = 11.5 min.

(1S,10b*S*)-9-chloro-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2H)-one 5,5-dioxide (3d): R_f = 0.56 (PE/EA, 3:1); White solid, 39.1 mg, 93% yield, 98% ee, >20:1 dr, [α]²⁸_D = -35.0 (c 1.5, CHCl₃); m.p. 188.0-188.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.51-7.32 (m, 5H), 7.24-7.18 (m, 2H), 7.11 (s, 1H), 4.37 (d, J = 8.7 Hz, 1H), 3.63 (dd, J = 18.1, 8.7 Hz, 1H), 2.88 (d, J = 18.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 171.5, 147.8, 138.1, 132.0, 131.6, 129.9-129.4 (m), 128.8, 127.1, 124.3 (q, J =

286.8 Hz), 120.7, 120.1, 73.6 (q, J = 30.1 Hz), 45.4, 38.5 (q, J = 2.3 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -76.08; HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{12}\text{ClF}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 418.0122, found 418.0123; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 9.2 min(major), t_2 = 10.3 min.

(1*S,10bS*)-8-chloro-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[*e*]pyrrololo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3e): R_f = 0.34 (PE/EA, 3:1); White solid, 37.1 mg 89% yield, 98% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = 44.5 (c 1.5, CHCl_3); m.p. 185.0-185.6 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.25-7.14 (m, 4H), 7.09-6.94 (m, 3H), 6.88 (d, J = 8.6 Hz, 1H), 4.21 (d, J = 8.8 Hz, 1H), 3.46 (dd, J = 18.2, 8.8 Hz, 1H), 2.67 (d, J = 18.1 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.6, 149.5, 138.4, 137.3, 130.4 (d, J = 2.0 Hz), 129.6, 128.7, 127.1, 126.7, 124.4 (q, J = 286.6 Hz), 120.2-119.8 (m), 117.2, 73.6 (q, J = 30.3 Hz), 45.32, 38.7 (q, J = 2.5 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -76.58; HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{12}\text{ClF}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 418.0122, found 418.0119; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 9.4 min (major), t_2 = 10.7 min.

(1*S,10bS*)-9-bromo-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[*e*]pyrrololo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3f): R_f = 0.58 (PE/EA, 3:1); White solid, 37.0 mg, 80% yield, 98% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = -111.03 (c 1.5, CHCl_3); m.p. 175.5-176.0 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.40 (dd, J = 8.7, 2.3 Hz, 1H), 7.27-7.18 (m, 3H), 7.10-6.95 (m, 4H), 4.20 (d, J = 8.8 Hz, 1H), 3.46 (dd, J = 18.3, 8.8 Hz, 1H), 2.71 (d, J = 18.2 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.6, 148.3, 138.1, 134.5, 132.6 (d, J = 2.0 Hz), 129.5, 128.8, 127.1, 124.3 (q, J = 286.7 Hz), 121.0, 120.3, 119.3, 73.5 (q, J = 30.4 Hz), 45.3, 38.5 (q, J = 2.5 Hz); ^{19}F NMR (376 MHz, Chloroform-*d*) δ -70.14, -76.13; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{11}\text{BrF}_3\text{NO}_4\text{SNa}^+$ ($\text{M}+\text{Na}$) $^+$ 483.9437, found 483.9436; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 14.1 min (major), t_2 = 16.0 min.

(1*S,10bS*)-1-phenyl-9,10b-bis(trifluoromethyl)-1,10b-dihydrobenzo[*e*]pyrrololo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3g): R_f = 0.48 (PE/EA, 3:1); Light yellow solid, 16.4 mg, 37% yield, 97% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = 16.0 (c 1.0, CHCl_3); m.p. 199.2-200 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.56 (d, J = 8.5 Hz, 1H), 7.30-7.16 (m, 5H), 7.02 (s, 2H), 4.25 (d, J = 8.8 Hz, 1H), 3.49 (dd, J = 18.3, 8.8 Hz, 1H), 2.75 (d, J = 18.3 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.4, 151.5, 138.0, 129.6, 129.0, 128.9, 128.6 (q, J = 3.7 Hz), 128.0 (q, J = 12.0 Hz), 127.3, 124.3 (q, J = 286.6 Hz), 122.5 (q, J = 271.0 Hz), 120.3, 119.6, 73.7 (q, J = 30.3 Hz), 45.5, 38.4 (q, J = 2.4 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -63.01, -76.10; HRMS (ESI) m/z calculated for $\text{C}_{18}\text{H}_{11}\text{F}_6\text{NO}_4\text{SNa}^+$ ($\text{M}+\text{Na}$) $^+$ 474.0205, found 474.0200; HPLC (Chiralpak IGX2-H column, hexane/iPrOH = 90/10, 1.0 mL/min, 210 nm): t_1 = 17.2 min, t_2 = 18.4 min (major).

(1*S,10bS*)-9-methyl-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[*e*]pyrrololo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3h): R_f = 0.34 (PE/EA, 3:1); White solid, 38.9 mg, 98% yield, 99% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = 17.2 (c 1.0, CHCl_3); m.p. 146.3-146.9 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.25-7.13 (m, 3H), 7.11-6.96 (m, 4H), 6.69 (s, 1H), 4.21 (d, J = 8.7 Hz, 1H), 3.51-3.38 (m, 1H), 2.73-2.56 (m, 1H), 2.06 (s, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.2, 147.3, 138.9, 136.4, 132.0, 130.2, 129.3, 128.4, 127.2, 124.6 (q, J = 2.6 Hz), 119.0, 118.3, 73.7 (q, J = 29.7 Hz), 45.4, 38.8 (q, J = 2.6 Hz), 20.6; ^{19}F NMR (376 MHz, CDCl_3) δ -70.37, -76.76; HRMS (ESI) m/z calculated for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 398.0668, found 398.0670; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1

= 14.0 min (major), t_2 = 15.6 min.

(1*S,10bS*)-9-(tert-butyl)-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3i): R_f = 0.55 (PE/EA, 3:1); White solid, 42.6 mg, 97% yield, 99% ee, >20:1 dr, $[\alpha]^{28}_D$ = 12.0 (*c* 1.0, CHCl₃); m.p. 164.0-164.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.31 (dd, *J* = 8.7, 2.2 Hz, 1H), 7.25-7.14 (m, 3H), 7.12-7.01 (m, 3H), 6.83 (d, *J* = 2.3 Hz, 1H), 4.25(d, *J* = 8.8 Hz, 1H), 3.59-3.38 (m, 1H), 2.71-2.55 (m, 1H), 0.99 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 172.3, 149.7, 147.0, 139.2, 129.5, 128.6, 128.2, 127.3, 127.2, 124.6 (q, *J* = 286.2 Hz), 118.8, 118.0, 73.8 (q, *J* = 30.1 Hz), 45.4, 39.0 (q, *J* = 2.5 Hz), 34.5, 30.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -70.54, -77.34; HRMS (ESI) m/z calculated for C₂₁H₂₁F₃NO₄S⁺ (M+H)⁺ 440.1138, found 440.1136; HPLC (Chiralpak IG-H column, hexane/iPrOH = 90/10, 1.0 mL/min, 210 nm): t_1 = 11.6 min, t_2 = 12.6 min (major).


(1*S,10bS*)-1,9-diphenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3j): R_f = 0.58 (PE/EA, 3:1); White solid, 42.4 mg, 92% yield, 99% ee, 17:1 dr, $[\alpha]^{28}_D$ = -71.3 (*c* 1.5, CHCl₃); m.p. 89.5-90.0 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.56-7.47 (m, 1H), 7.45-7.37 (m, 3H), 7.36-7.27 (m, 4H), 7.17 (d, *J* = 7.2 Hz, 2H), 7.13-7.03 (m, 3H), 4.33 (d, *J* = 8.8 Hz, 1H), 3.64-3.45 (m, 1H), 2.80-2.62 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 172.1, 148.6, 140.0, 139.1, 138.6, 130.3, 129.6, 129.1, 128.9, 128.6, 128.2, 127.4, 127.0, 124.6 (q, *J* = 286.6 Hz), 119.7, 119.0, 73.7 (q, *J* = 30.2 Hz), 45.5, 38.9 (q, *J* = 2.3 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -70.28, -76.98; HRMS (ESI) m/z calculated for C₂₃H₁₇F₃NO₄S⁺ (M+H)⁺ 460.0825, found 460.0826; HPLC (Chiralpak IG-H column, hexane/iPrOH = 90/10, 1.0 mL/min, 210 nm): t_1 = 17.3 min, t_2 = 19.6 min (major).

(1*S,10bS*)-9-methoxy-1-phenyl-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (3k): R_f = 0.25 (PE/EA, 3:1); White solid, 40.5 mg, 98% yield, 99% ee, >20:1 dr, $[\alpha]^{28}_D$ = -17.4 (*c* 1, CHCl₃); m.p. 156.5-157.2 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.24-7.17 (m, 3H), 7.13-7.00 (m, 3H), 6.81 (dd, *J* = 9.1, 2.9 Hz, 1H), 6.35 (d, *J* = 2.9 Hz, 1H), 4.22 (d, *J* = 8.7 Hz, 1H), 3.52-3.39 (m, 4H), 2.71-2.57 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 172.2, 157.1, 142.9, 139.0, 129.5, 128.5, 127.2, 124.5 (q, *J* = 286.6 Hz) 120.3, 119.62 117.5, 114.7, 114.6, 73.7 (q, *J* = 30.1 Hz), 55.7, 45.4, 39.0 (q, *J* = 2.3 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -70.43, -76.95; HRMS (ESI) m/z calculated for C₁₈H₁₅F₃NO₅S⁺ (M+H)⁺ 414.0618, found 414.0619; HPLC (Chiralpak IC-H column, hexane/iPrOH = 90/10, 1.0 mL/min, 210 nm): t_1 = 24.5 min (major), t_2 = 26.2 min.


(1*S,10bS*)-1-(4-fluorophenyl)-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4b): R_f = 0.40 (PE/EA, 3:1); White solid, 38.9 mg, 97% yield, 99% ee, 17:1 dr, $[\alpha]^{28}_D$ = 66.0 (*c* 1.5, CHCl₃); m.p. 146.0-146.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.40-7.29 (m, 1H), 7.17 (d, *J* = 8.3 Hz, 1H), 7.07-6.98 (m, 3H), 6.95-6.80 (m, 3H), 4.25 (d, *J* = 8.7 Hz, 1H), 3.46 (dd, *J* = 18.3, 8.8 Hz, 1H), 2.61 (d, *J* = 18.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 171.8, 162.2 (d, *J* = 249.0 Hz), 149.4, 134.6 (d, *J* = 3.6 Hz), 131.8, 129.6, 128.9, 126.4, 124.4 (q, *J* = 286.6 Hz), 119.6, 118.5, 116.5 (d, *J* = 21.6 Hz), 73.7 (q, *J* = 30.5 Hz), 44.7, 38.9; ¹⁹F NMR (376 MHz, CDCl₃) δ -70.34, -76.61, -112.25; HRMS (ESI) m/z calculated for C₁₇H₁₂F₄NO₄S⁺ (M+H)⁺ 402.0418, found 402.0419; HPLC (Chiralpak IC-H column, hexane/iPrOH = 85/15, 1.0 mL/min, 210 nm): t_1 = 14.5 min (major), t_2 = 16.4 min.

(1*S,10bS*)-1-(4-chlorophenyl)-10b-(trifluoromethyl)-1,10b-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4c): R_f = 0.40 (PE/EA, 3:1);


White solid, 40.3 mg, 96% yield, 98% *ee*, 17:1 dr, $[\alpha]^{28}_D = 44.8$ (*c* 1.5, CHCl_3); m.p. 131.0-131.5 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.42-7.31 (m, 1H), 7.21-7.13 (m, 3H), 7.12-6.78 (m, 4H), 4.24 (d, *J* = 8.6 Hz, 1H), 3.46 (dd, *J* = 18.2, 8.7 Hz, 1H), 2.59 (dd, *J* = 18.0, 2.4 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.7, 149.3, 137.2, 134.4, 131.9, 129.6, 129.6, 128.5, 126.5, 124.4 (q, *J* = 286.8 Hz), 119.6, 118.4, 73.6 (q, *J* = 29.9 Hz), 44.8, 38.8 (q, *J* = 2.8 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -70.33, -76.71; HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{11}\text{ClF}_3\text{NO}_4\text{SNa}^+$ ($\text{M}+\text{Na}$)⁺ 439.9942, found 439.9942; HPLC (Chiralpak IC-H column, hexane/*iPrOH* = 85/15, 1.0 mL/min, 210 nm): t_1 = 13.9 min (major), t_2 = 16.5 min.




(1*S*,10*bS*)-1-(4-bromophenyl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4d):** R_f = 0.39 (PE/EA, 3:1); White solid, 44.9 mg, 97% yield, 99% *ee*, 17:1 dr, $[\alpha]^{28}_D = 95.2$ (*c* 1.5, CHCl_3); m.p. 120.8-121.3 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.41-7.29 (m, 3H), 7.19 (d, *J* = 8.2 Hz, 1H), 7.06 (t, *J* = 7.7 Hz, 1H), 6.92 (d, *J* = 7.5 Hz, 3H), 4.22 (d, *J* = 8.7 Hz, 1H), 3.46 (dd, *J* = 18.1, 8.7 Hz, 1H), 2.59 (dd, *J* = 18.2, 2.3 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.7, 149.3, 137.7, 132.6, 131.9, 129.6 (d, *J* = 1.5 Hz), 128.7, 126.6, 124.3 (q, *J* = 286.7 Hz), 122.5, 119.6, 118.4, 73.5 (q, *J* = 30.1 Hz), 44.9, 38.7 (q, *J* = 2.5 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -70.32, -76.75; HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{12}\text{BrF}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$)⁺ 461.9617, found 461.9617; HPLC (Chiralpak IC-H column, hexane/*iPrOH* = 85/15, 1.0 mL/min, 210 nm): t_1 = 14.4 min (major), t_2 = 17.7 min.



(1*S*,10*bS*)-1-(p-tolyl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4e):** R_f = 0.44 (PE/EA, 3:1); White solid, 38.7 mg, 97% yield, 99% *ee*, 20:1 dr, $[\alpha]^{28}_D = 76.7$ (*c* 1.5, CHCl_3); m.p. 134.0-134.7 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.36-7.27 (m, 1H), 7.15 (d, *J* = 8.3 Hz, 1H), 7.07-6.86 (m, 6H), 4.20 (d, *J* = 8.7 Hz, 1H), 3.44 (dd, *J* = 18.1, 8.7 Hz, 1H), 2.61 (d, *J* = 18.1 Hz, 1H), 2.21 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.2, 149.4, 138.2, 135.7, 131.5, 130.0, 129.8, 127.0, 126.3, 124.6 (q, *J* = 286.4 Hz), 119.4, 118.8, 73.8 (q, *J* = 29.8 Hz), 45.1, 39.0 (q, *J* = 2.6 Hz), 21.0; ^{19}F NMR (376 MHz, CDCl_3) δ -76.72; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$)⁺ 398.0668, found 398.0669; HPLC (Chiralpak IG-H column, hexane/*iPrOH* = 92/8, 1.0 mL/min, 210 nm): t_1 = 23.2 min, t_2 = 24.6 min (major).




(1*S*,10*bS*)-1-(4-methoxyphenyl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4f):** R_f = 0.40 (PE/EA, 3:1); White solid, 37.4 mg, 90% yield, 99% *ee*, 20:1 dr, $[\alpha]^{28}_D = 70.0$ (*c* 1.5, CHCl_3); m.p. 60.0-60.5 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.37-7.30 (m, 1H), 7.15 (dd, *J* = 8.3, 1.2 Hz, 1H), 7.08-7.00 (m, 1H), 6.95 (d, *J* = 8.9 Hz, 3H), 6.70 (d, *J* = 8.5 Hz, 2H), 4.20 (d, *J* = 8.6 Hz, 1H), 3.70 (s, 3H), 3.52-3.37 (m, 1H), 2.68-2.53 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.3, 159.2, 149.3, 131.5, 130.7, 129.8, 128.3, 126.3, 124.5 (q, *J* = 286.7 Hz), 119.4, 118.8, 114.6, 73.83 (q, *J* = 29.7 Hz), 55.2, 44.7, 39.1; ^{19}F NMR (376 MHz, CDCl_3) δ -70.53, -76.65; HRMS (ESI) m/z calculated for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NO}_5\text{S}^+$ ($\text{M}+\text{H}$)⁺ 414.0618, found 414.0612; HPLC (Chiralpak IC-H column, hexane/*iPrOH* = 70/30, 1.0 mL/min, 230 nm): t_1 = 9.9 min (major), t_2 = 11.4 min.




(1*S*,10*bS*)-1-(4-nitrophenyl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4g):** R_f = 0.25 (PE/EA, 3:1); Light yellow solid, 35.6 mg 83% yield, 99% *ee*, >20:1 dr, $[\alpha]^{28}_D = 55.2$ (*c* 1.5, CHCl_3); m.p. 246.0-246.5 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.08 (d, *J* = 8.4 Hz, 2H), 7.38 (t, *J* = 7.9 Hz, 1H), 7.31-7.18 (m, 3H), 7.05 (t, *J* = 7.7 Hz, 1H), 6.88 (d, *J* = 8.0 Hz, 1H), 4.39 (d, *J* = 8.7


Hz, 1H), 3.52 (dd, J = 18.2, 8.7 Hz, 1H), 2.62 (d, J = 18.2 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.1, 149.3, 147.5, 145.7, 132.3, 129.2, 128.3, 126.8, 124.6, 124.3 (q, J = 286.5 Hz), 119.9, 118.0, 73.30 (q, J = 30.4 Hz), 45.0, 38.4; ^{19}F NMR (376 MHz, CDCl_3) δ -76.73; $\text{C}_{17}\text{H}_{12}\text{F}_3\text{N}_2\text{O}_6\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 429.0363, found 429.0366; HPLC (Chiralpak IC-H column, hexane/iPrOH = 70/30, 1.0 mL/min, 254 nm): t_1 = 19.5 min (major), t_2 = 22.2 min.




(1*S*,10*bS*)-1-(3-chlorophenyl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4h):** R_f = 0.50 (PE/EA, 3:1); White solid, 18.1 mg, 43% yield, 99% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = 68.6 (*c* 1.5, CHCl_3); m.p. 157.5-158.0 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.41-7.32 (m, 1H), 7.23-7.02 (m, 5H), 6.95 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 4.21 (d, J = 8.7 Hz, 1H), 3.52-3.39 (m, 1H), 2.71-2.55 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.5, 149.4, 140.6, 135.1, 131.9, 131.0, 129.4, 128.7, 128.0, 126.5, 124.4 (q, J = 286.5 Hz), 124.6, 119.7, 118.4, 73.6 (q, J = 30.4 Hz), 45.1, 38.6; ^{19}F NMR (376 MHz, CDCl_3) δ -76.62; HRMS (ESI) m/z calculated for $\text{C}_{17}\text{H}_{12}\text{ClF}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 418.0122, found 418.0120; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 10.4 min (major), t_2 = 11.2 min.



(1*S*,10*bS*)-1-(naphthalen-2-yl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4j):** R_f = 0.53 (PE/EA, 3:1); Light yellow solid, 42.6 mg, 98% yield, 99% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = 120.1 (*c* 1.5, CHCl_3); m.p. 161.5-162.0 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.77-7.67 (m, 2H), 7.68-7.57 (m, 2H), 7.53-7.40 (m, 2H), 7.25-7.19 (m, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.11-6.95 (m, 2H), 6.87 (t, J = 7.7 Hz, 1H), 4.43 (d, J = 8.7 Hz, 1H), 3.54 (dd, J = 18.1, 8.8 Hz, 1H), 2.69 (d, J = 18.1 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.1, 149.4, 136.1, 133.0, 132.6, 131.6, 129.8, 129.7, 127.8, 127.7, 126.9, 126.7, 126.4, 124.6 (q, J = 286.6 Hz), 119.4, 118.7, 73.6 (q, J = 29.5 Hz), 45.6, 39.0; ^{19}F NMR (376 MHz, CDCl_3) δ -76.89; HRMS (ESI) m/z calculated for $\text{C}_{21}\text{H}_{15}\text{F}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 434.0668, found 434.0668; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 14.0 min (major), t_2 = 15.3 min.






(1*R*,10*bS*)-1-(furan-2-yl)-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4k):** R_f = 0.38 (PE/EA, 3:1); Light yellow solid, 34.8 mg, 93% yield, 95% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = -41.0 (*c* 1.5, CHCl_3); m.p. 122.7-123.2 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.41-7.32 (m, 1H), 7.26 (s, 1H), 7.21-7.08 (m, 3H), 6.17-6.07 (m, 2H), 4.40 (d, J = 8.6 Hz, 1H), 3.44-3.26 (m, 1H), 2.71 (dd, J = 17.8, 2.2 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.9, 150.0, 149.1, 142.8, 131.6, 128.0 (d, J = 2.0 Hz), 126.4, 124.2 (d, J = 287.5 Hz), 119.4, 118.01, 110.5, 108.9, 73.2 (q, J = 29.9 Hz), 39.6, 36.2 (d, J = 2.6 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -75.20; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{F}_3\text{NO}_5\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 374.0305, found 374.0306; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 13.7 min (major), t_2 = 15.8 min.




(1*R*,10*bS*)-1-ethyl-10*b*-(trifluoromethyl)-1,10*b*-dihydrobenzo[e]pyrrolo[1,2-c][1,2,3]oxathiazin-3(2*H*)-one 5,5-dioxide (4l):** R_f = 0.36 (PE/EA, 3:1); colorless oil, 27.6 mg, 82% yield, 95% ee, >20:1 dr, $[\alpha]^{28}\text{D}$ = -96.9 (*c* 1.5, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.65-7.48 (m, 1H), 7.45 (d, J = 4.6 Hz, 2H), 7.28 (d, J = 2.0 Hz, 1H), 3.15-2.89 (m, 2H), 2.63-2.44 (m, 1H), 1.57-1.38 (m, 1H), 1.20-0.97 (m, 1H), 0.89 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.1, 149.8, 131.9, 127.9 (q, J = 2.4 Hz), 126.9, 124.6 (q, J = 289.0 Hz), 120.0, 117.5, 74.2 (q, J = 29.4 Hz), 40.3, 34.06 (q, J = 2.7 Hz), 23.2, 10.0; ^{19}F NMR (376 MHz, CDCl_3) δ -72.54, -73.56; HRMS (ESI) m/z calculated for $\text{C}_{13}\text{H}_{13}\text{F}_3\text{NO}_4\text{S}^+$ ($\text{M}+\text{H}$) $^+$ 336.0512,

found 336.0512; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 13.6 min (major), t_2 = 19.8 min.





5. Transformations of product 3a



(4*S*,5*S*)-5-(2-hydroxyphenyl)-4-phenyl-5-(trifluoromethyl)pyrrolidin-2-one (5): The compound 5 was synthesized according to reported literature. To a suspension of LiAlH₄ (1.0 mmol) in THF (5 mL), 3a (0.2 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 1 hour, TLC showed one spot. Water was added to destroy the lithium aluminum hydride, the aqueous layer was extracted with EtOAc three times, the combined organic layers were dried and concentrated to provide the crude product. Purification by

chromatography on silica (PE/EA = 5:1) gave the product as white solid (61.7 mg, 55% yield, 98% ee). R_f = 0.30 (PE/EA, 3:1); $[\alpha]^{25}_D$ = -21.3 (*c* 1.0, CHCl₃); m.p. 52.1–52.6 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.41 (d, *J* = 8.1 Hz, 1H), 7.35–7.23 (m, 3H), 7.20–7.11 (m, 3H), 7.02–6.93 (m, 1H), 6.87 (dd, *J* = 8.1, 1.5 Hz, 1H), 3.79–3.57 (m, 2H), 3.42 (td, *J* = 9.7, 4.3 Hz, 1H), 2.38–2.19 (m, 1H), 2.16–2.04 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 150.5, 135.5, 130.9, 129.7, 128.3, 128.0, 127.5 (d, *J* = 3.1 Hz), 125.8, 124.7 (q, *J* = 287.0 Hz), 119.7, 118.6, 69.72 (q, *J* = 27.3 Hz), 59.6, 50.1, 31.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -67.67, -68.76; HRMS (ESI) *m/z* calculated for C₁₇H₁₇F₃NO⁺ (M+H)⁺ 308.1257, found 308.1256; HPLC (Chiralpak IG-H column, hexane/iPrOH = 88/12, 1.0 mL/min, 210 nm): t₁ = 11.7 min (major), t₂ = 47.4 min.



Scheme S2 2D-NOESY NMR of the compound **6**


(1*S*,3*R*,10*bS*)-3-hydroxy-1-phenyl-10*b*-(trifluoromethyl)-1,2,3,10*b*-tetrahydrobenzo[*e*]pyrrolo[1,2-*c*][1,2,3]oxathiazine 5,5-dioxide (**6**):** The solution of BH₃ (1M in THF, 0.8 ml, 0.8 mmol) in THF (2 mL) was added **3a** (0.2 mmol, 76.6 mg). The reaction mixture was stirred for 4 h at 60 °C. Purification by column chromatography on silica gel (PE/EA = 10:1) afforded the product **6** as white solid (77.3 mg, 68% yield, 98% ee). R_f = 0.53 (PE/EA, 3:1); $[\alpha]^{28}_D$ = 42.7 (*c* 1.0, CHCl₃); m.p. 45.0–45.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.26–7.08 (m, 4H), 7.08–6.97 (m, 1H), 6.91–6.72 (m, 3H), 6.55 (d, *J* = 8.1 Hz, 1H), 6.24–6.16 (m, 1H), 4.46 (t, *J* = 8.3 Hz, 1H), 3.34 (s, 1H), 2.40 (q, *J* = 8.8, 6.6 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 151.1, 136.1, 130.8, 129.5, 129.2 (d, *J* = 3.4 Hz), 128.3, 128.1, 125.1, 124.8 (q, *J* = 284.8 Hz), 119.3, 116.1, 88.3, 76.3 (q, *J* = 29.7 Hz), 52.1, 38.5; ¹⁹F NMR (376 MHz, CDCl₃) δ -71.66, -73.83; HRMS (ESI) *m/z* calculated for

$C_{17}H_{13}F_3NO_3S^+$ ($M-OH$)⁺ 368.0563, found 368.0565; HPLC (Chiralpak IC-H column, hexane/iPrOH = 80/20, 1.0 mL/min, 210 nm): t_1 = 7.6 min (major), t_2 = 8.9 min. The relative stereochemistry of compound **6** was determined by 2D-NOESY NMR (**Scheme S2**). No NOE effect was observed for between H^1 and H^4 .


(1*S*,10*bS*)-1-phenyl-10*b*-(trifluoromethyl)-1,2,3,10*b*-tetrahydrobenzo[*e*]pyrrolo[1,2-*c*][1,2,3]oxathiazine 5,5-dioxide (7):** Compound **6** (0.1 mmol, 38.5mg) was dissolved in DCM (0.5ml) and cooled to -10 °C. Et₃SiH (3.2 eq, 0.32 mmol) was added to the mixture, and then BF₃·Et₂O (3.2eq, 0.32mmol) was added slowly. The temperature of the reaction system increased to 0 °C within 30 min and reacted under 0 °C for another 10 min. Purification by column chromatography on silica gel (PE/EA = 10:1) afforded the product **7** as white solid (30.8 mg 84% yield, 98% ee). R_f = 0.56 (PE/EA, 3:1); White solid, 30.8 mg, 84% yield, 98% ee, $[\alpha]^{28}_D$ = 28.7 (c 1.5, CHCl₃); m.p. 99.4-100.0 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.21 (d, J = 7.2 Hz, 1H), 7.17-7.07 (m, 3H), 7.03 (dd, J = 8.2, 1.3 Hz, 1H), 6.88-6.71 (m, 3H), 6.56 (d, J = 8.1 Hz, 1H), 4.42-4.29 (m, 1H), 4.18-3.97 (m, 1H), 3.92-3.77 (m, 1H), 2.45-2.30 (m, 1H), 2.32-2.13 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 151.3, 137.0, 130.6, 129.1, 129.0 (d, J = 3.4 Hz), 128.3, 127.9, 125.5 (q, J = 285.0 Hz), 125.0, 119.3, 117.2, 76.1 (q, J = 28.9 Hz), 55.1, 52.4, 31.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -67.23, -72.82; HRMS (ESI) m/z calcd for $C_{17}H_{15}F_3NO_3S^+$ ($M+H$)⁺ 370.0719, found 370.0719; HPLC (Chiralpak IC-H column, hexane/iPrOH = 98/2, 1.0 mL/min, 210 nm): t_1 = 14.3 min (major), t_2 = 15.5 min.





6. X-ray structure for compound 3e



A single crystal of the compound **3e** (CCDC 1919445) was grown from its solution in dichloromethane/isopropanol (1/3), which is suitable for X-ray diffraction analysis. The correctness of the X-ray data and the structure had been checked by using the Check CIF utility on the submission Web site: <http://checkcif.iucr.org>







Copy of NMR for New Compounds

















































































































































































































Copy of HRMS for New Compounds


ZZZ-3-1E. HRMS (ESI) m/z calcd for $C_{17}H_{13}F_3NO_4S^+$ ($M+H$)⁺ 384.05119, found 384.05130.

00082 #22 RT: 0.30 AV: 1 NL: 1.40E7
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-22B. HRMS (ESI) m/z calcd for $C_{17}H_{12}F_4NO_4S^+$ ($M+H$)⁺ 402.04177, found 402.04153.


00090 #42 RT: 0.58 AV: 1 NL: 3.88E4
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-26B. HRMS (ESI) m/z calcd for $C_{17}H_{12}F_4NO_4S^+$ ($M+H$)⁺ 402.04177, found 402.04144.

00092 #15 RT: 0.20 AV: 1 NL: 3.86E5


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-15A. HRMS (ESI) m/z calcd for $C_{17}H_{12}ClF_3NO_4S^+$ ($M+H$)⁺ 418.01222, found 418.01227.


00083 #16 RT: 0.21 AV: 1 NL: 2.34E5

T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-15B. HRMS (ESI) m/z calcd for $C_{17}H_{12}ClF_3NO_4S^+$ ($M+H$)⁺ 418.01222, found 418.01187.

00084 #25 RT: 0.34 AV: 1 NL: 2.05E5
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-26A. HRMS (ESI) m/z calcd for $C_{17}H_{11}BrF_3NO_4SNa^+$ ($M+Na$)⁺ 483.94365, found 483.94360.


00091 #15 RT: 0.20 AV: 1 NL: 5.46E6
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-18D. HRMS (ESI) m/z calcd for $C_{18}H_{11}F_6NO_4SNa^+$ ($M+Na$)⁺ 474.02052, found 474.02002.

00089 #13 RT: 0.17 AV: 1 NL: 4.91E5


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-15C. HRMS (ESI) m/z calcd for $C_{18}H_{15}F_3NO_4S^+$ ($M+H$)⁺ 398.06684, found 398.06696.


00085 #23 RT: 0.31 AV: 1 NL: 1.77E7

T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-18B. HRMS (ESI) m/z calcd for $C_{21}H_{21}F_3NO_4S^+$ ($M+H$)⁺ 440.11379, found 440.11356.

00087 #17 RT: 0.22 AV: 1 NL: 1.16E7
T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-18C. HRMS (ESI) m/z calcd for $C_{23}H_{17}F_3NO_4S^+$ ($M+H$)⁺ 460.08249, found 460.08255.

00088 #31 RT: 0.45 AV: 1 NL: 4.34E6
T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-15D. HRMS (ESI) m/z calcd for $C_{18}H_{15}F_3NO_5S^+$ ($M+H$)⁺ 414.06175, found 414.06198.

00086 #16 RT: 0.21 AV: 1 NL: 2.13E7
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-2-96A. HRMS (ESI) m/z calcd for $C_{17}H_{12}F_4NO_4S^+$ ($M+H$)⁺ 402.04177, found 402.04178.


00094 #11 RT: 0.14 AV: 1 NL: 8.75E6
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-2-96C. HRMS (ESI) m/z calcd for $C_{17}H_{12}BrF_3NO_4S^+$ ($M+H$)⁺ 461.96170, found 461.96167.

00095 #11 RT: 0.14 AV: 1 NL: 3.67E6


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-2-96B. HRMS (ESI) m/z calcd for $C_{17}H_{11}ClF_3NO_4SNa^+$ ($M+Na$)⁺ 439.99416, found 439.99423.



00096 #12 RT: 0.15 AV: 1 NL: 2.67E7

T: FTMS + p ESI Full ms [100.00-1000.00]





ZZZ-3-22A. HRMS (ESI) m/z calcd for $C_{18}H_{15}F_3NO_4S^+$ ($M+H$)⁺ 398.06684, found 398.06689.

00098 #16 RT: 0.21 AV: 1 NL: 4.01E6
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-1D. HRMS (ESI) m/z calcd for $C_{18}H_{15}F_3NO_5S^+$ ($M+H$)⁺ 414.06175, found 414.06122.


00097 #15 RT: 0.20 AV: 1 NL: 7.74E5
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-1C. HRMS (ESI) m/z calcd for $C_{17}H_{12}F_3N_2O_6S^+$ ($M+H$)⁺ 429.03627, found 429.03656.

00040 #15 RT: 0.21 AV: 1 NL: 5.60E3


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-9B. HRMS (ESI) m/z calcd for $C_{17}H_{12}ClF_3NO_4S^+$ ($M+H$)⁺ 418.01222, found 418.01202.

00099 #18 RT: 0.24 AV: 1 NL: 6.29E5


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-9C. HRMS (ESI) m/z calcd for $C_{21}H_{15}F_3NO_4S^+$ ($M+H$)⁺ 434.06684, found 434.06677.

000100 #17 RT: 0.22 AV: 1 NL: 3.23E5


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-1A. HRMS (ESI) m/z calcd for $C_{15}H_{11}F_3NO_5S^+$ ($M+H$)⁺ 374.03045, found 374.03055.

000101 #12 RT: 0.15 AV: 1 NL: 1.51E7


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-7D. HRMS (ESI) m/z calcd for $C_{13}H_{13}F_3NO_4S^+$ ($M+H$)⁺ 336.05119, found 336.05121.

000105 #24 RT: 0.32 AV: 1 NL: 2.59E6


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-7C. HRMS (ESI) m/z calcd for $C_{14}H_{15}F_3NO_4S^+$ ($M+H$)⁺ 350.06684, found 350.06699.


000102 #19 RT: 0.25 AV: 1 NL: 1.08E7

T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-7A. HRMS (ESI) m/z calcd for $C_{14}H_{15}F_3NO_4S^+$ ($M+H$)⁺ 350.06684, found 350.06689.

000103 #8 RT: 0.10 AV: 1 NL: 1.88E7
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-7B. HRMS (ESI) m/z calcd for $C_{18}H_{23}F_3NO_4S^+$ ($M+H$)⁺ 406.12944, found 406.12924.


000104 #18 RT: 0.24 AV: 1 NL: 9.34E5
T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-28A. HRMS (ESI) m/z calcd for $C_{17}H_{17}F_3NO^+$ ($M + H$)⁺ 308.12568, found 308.12555.

000106 #20 RT: 0.27 AV: 1 NL: 9.62E4


T: FTMS + p ESI Full ms [100.00-1000.00]



ZZZ-3-28D. HRMS (ESI) m/z calcd for $C_{17}H_{13}F_3NO_3S^+$ ($M - OH$)⁺ 368.05627, found 368.05646.


000107 #13 RT: 0.17 AV: 1 NL: 4.67E7

T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-3-60A. HRMS (ESI) m/z calcd for $C_{17}H_{15}F_3NO_3S^+$ ($M+H$)⁺ 370.07193, found 370.07193.

00039 #12 RT: 0.16 AV: 1 NL: 1.41E4
T: FTMS + p ESI Full ms [100.00-1000.00]




ZZZ-2-52. HRMS (ESI) m/z calcd for $C_{27}H_{33}N_4O_3^+$ ($M-\text{Cl}$)⁺ 461.25472, found 461.25443.




00132 #18 RT: 0.24 AV: 1 NL: 1.48E9
T: FTMS + p ESI Full ms [100.00-1000.00]




HPLC for racemic and pure enantioenriched sample **3a**




HPLC for racemic and pure enantioenriched sample **3b**



HPLC for racemic and pure enantioenriched sample **3c**




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称 度 EP
1	10.238	48.24	90.8264	191.61	0.440	1.32




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称 度 EP
1	10.138	99.05	142.4311	308.42	0.428	1.36

HPLC for racemic and pure enantioenriched sample **3d**




峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	9.214	BB	0.2627	2345.02075	139.0970
2	10.246	BB	0.2848	2484.55127	136.2109






峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	9.207	MM R	0.2970	1.19929e4	672.9564
2	10.251	MM R	0.2544	96.63966	6.3307



HPLC for racemic and pure enantioenriched sample **3e**




HPLC for racemic and pure enantioenriched sample **3f**




HPLC for racemic and pure enantioenriched sample **3g**

HPLC for racemic and pure enantioenriched sample **3h**




峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	13.949	BB	0.3748	9370.86426	389.3643
2	15.575	BB	0.4139	1.02106e4	381.9708




峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	13.954	BB	0.3992	2.95731e4	1168.6740
2	15.641	BB	0.3135	167.22672	6.5136

HPLC for racemic and pure enantioenriched sample **3i**




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	11.570	52.68	71.7763	181.84	0.368	1.15


HPLC for racemic and pure enantioenriched sample **3j**



峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	17.210	51.82	48.9552	90.00	0.500	1.18




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	11.555	0.62	2.4636	6.19	0.373	n.a.




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	17.268	0.74	4.5345	8.69	0.494	1.07

HPLC for racemic and pure enantioenriched sample **3k**



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	24.550	BV	0.5968	1.11363e4	292.1033
2	26.117	VB	0.6283	1.22725e4	304.4364



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	24.527	BB	0.5912	1.80848e4	478.2661
2	26.180	BB	0.4116	79.97885	2.3585

HPLC for racemic and pure enantioenriched sample **4b**



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	14.453	BB	0.4510	3848.14404	134.8077
2	16.373	BB	0.4853	4186.27393	133.7030






信号 3: DAD1 C, Sig=210,8 Ref=360,100

峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	14.452	BB	0.4480	1.05281e4	369.9451
2	16.393	BB	0.3587	69.37284	2.3347


HPLC for racemic and pure enantioenriched sample **4c**




HPLC for racemic and pure enantioenriched sample **4d**



HPLC for racemic and pure enantioenriched sample **4e**




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	22.890	51.47	92.2570	158.93	0.542	1.13




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	23.151	0.71	0.8350	1.43	0.554	n.a.

HPLC for racemic and pure enantioenriched sample **4f**



信号 2: DAD1 B, Sig=230,8 Ref=360,100



峰序号	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	9.887	BB	0.2823	649.10260	35.6726
2	11.374	BB	0.3164	699.57166	34.2412





信号 2: DAD1 B, Sig=230,8 Ref=360,100

峰序号	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	9.894	BB	0.2814	4658.14551	257.0625
2	11.370	BB	0.2665	25.03966	1.3128


HPLC for racemic and pure enantioenriched sample **4g**




HPLC for racemic and pure enantioenriched sample **4h**



HPLC for racemic and pure enantioenriched sample **4j**




峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	13.940	BB	0.3891	1555.06543	61.4755
2	15.206	BB	0.4104	1667.90527	61.1178




峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	13.987	BB	0.3965	1.23441e4	482.48745
2	15.287	BB	0.3179	81.16329	3.09571

HPLC for racemic and pure enantioenriched sample **4k**




峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	13.757	BB	0.3668	3921.47534	166.4706
2	15.832	BB	0.4118	4119.40918	154.1367




峰	保留时间	类型	峰宽	峰面积	峰高
#	[min]		[min]	[mAU*s]	[mAU]
1	13.720	BB	0.3730	1.26511e4	532.8713
2	15.819	BB	0.3489	318.81372	11.9644

HPLC for racemic and pure enantioenriched sample **4l**



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	13.610	BB	0.3521	713.70056	30.8240
2	19.940	BB	0.4471	706.36975	22.5712



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	13.551	BB	0.3390	8337.15234	381.4297
2	19.847	BB	0.3708	205.60515	6.7606

HPLC for racemic and pure enantioenriched sample **4m**



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	12.527	BB	0.3596	3566.44873	154.36166
2	18.787	BB	0.4936	3888.78491	122.08109




信号 3: DAD1 C, Sig=210,8 Ref=360,100

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	12.554	BB	0.3367	4997.74609	230.6966
2	18.815	BB	0.3844	142.31018	4.4822

HPLC for racemic and pure enantioenriched sample **4n**




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	20.716	49.40	75.1893	148.62	0.475	1.05




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	20.648	98.19	122.2400	244.16	0.469	1.05

HPLC for racemic and pure enantioenriched sample **4o**




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	17.555	47.69	94.4127	163.08	0.533	1.18




峰序号	保留时间 min	相对峰面积 %	峰面积 mAU*min	峰高 mAU	峰宽 (50%)	不对称度 EP
1	17.608	97.58	167.8129	287.31	0.539	1.17

HPLC for racemic and pure enantioenriched sample 5



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	11.703	MM R	0.6838	1.48033e4	360.8089
2	46.074	BB	1.4303	1.40427e4	115.6786



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	11.678	VB	0.6301	2.82759e4	716.9333
2	47.368	MM R	1.2978	237.00111	3.0435

HPLC for racemic and pure enantioenriched sample 6



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	7.564	BV	0.4398	8672.61230	320.4353
2	8.789	VB	0.4940	9620.07910	315.2989



信号 3: DAD1 C, Sig=210,8 Ref=360,100


峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	7.643	BV	0.2861	7519.65869	409.6842
2	8.892	VB	0.2945	65.51433	2.9564

HPLC for racemic and pure enantioenriched sample 7



信号 3: DAD1 C, Sig=210,8 Ref=360,100

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	14.920	BV	0.4109	6597.92041	250.8217
2	16.094	VB	0.4391	7189.80811	256.4325



信号 3: DAD1 C, Sig=210,8 Ref=360,100

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]
1	14.305	BB	0.4445	1.22544e4	443.2915
2	15.507	BB	0.3607	115.59990	4.2311